AbbVie Licenses Nxera Gut Targeted EP4 Agonist

Company Nxera Pharma; AbbVie Event Type Global license agreement Modality Small molecule (oral, gut-targeted) Asset NXE0033744 Target EP4 (prostaglandin E2 receptor) Disease Area Inflammatory bowel disease Summary Previously missed November 4 transaction: Nxera Pharma licensed worldwide rights to its oral EP4 agonist NXE0033744 for inflammatory…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *